RetaMaps

Shantique Med Spa

Shantique Med Spa · 2780 Skypark Drive · Torrance, CA 90505

4.9· 75 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Shantique Med Spa is a physician-led med spa in Torrance, California, where, per its website, founder Shahinaz Soliman, MD, a board-certified family physician, directs care that includes aesthetic treatments, IV hydration and laser services such as BBL and Halo. The site also describes doctor-supervised weight loss built on monthly monitoring, customized diet plans and medication. On Google it has a 4.9-star rating across 75 reviews dating back to 2019, with 65 in the past year, and reviewers most often mention the staff, the team's knowledge and caring treatment.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.9
Google rating · 75 reviews
65
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-22. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.9 across 75 Google reviews. Of the 75 reviews we analyzed, 73 (97%) are positive (4–5★) and 2 (3%) are negative (1–2★).

What patients like

  • Friendly, helpful staff15 reviews
  • Knowledgeable, professional providers9 reviews
  • Feeling listened to9 reviews
  • Weight-loss results2 reviews

Common complaints

  • Scheduling or communication problems2 of 2 negative
5★
73
4★
0
3★
0
2★
1
1★
1

Most recent Google reviews

Kety B.★★★★★2026-09-22

Dr. Soliman is the best doctor I’ve ever had! She always listen to my medical issues and find all ways to give me the proper treatments and needed referrals. Her and her staff deserve 10 star for great service!

Sandra C.★★★★★2026-09-15

Doctor Soliman and her Practitioners always show concern for my health and find the best methods to improve my well being. When I can’t reach the office for any issue I may have, Dr. Soliman finds a way to helps me out by responding to me right away and make sure her staff or herself take care of my concerns. I’ve been under their care since 2013 and recommend her and her staff for they are always polite and respectful.

Francine C.★★★★★2026-08-28

Today I had a very nice consultation and scheduled my treatments for October. Very happy with everyone there very nice clean

Eugene I.★★★★★2026-08-22

I love the excellent service from the doctor, she is very compassionate and her knowledge is the best! I highly recommend Doctor Solomon!

Maria J.★★★★★2026-08-22

I had a last minute health issue and I called the office and got it resolved so quickly!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Torrance

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs